Back
Results - Announcements
Rubicon Research Ltd consolidated sales up 3.97% on year in Q2FY2026, net profit improved by 10.41%
14-Aug-2026, 07:35
Rubicon Research Ltd share price slipped 2.03% to Rs 1622.0. The Company's net profit expanded by 10.41% to Rs 84.78 crore, while revenue from operations slightly gained 3.97% to Rs 534.34 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.63%. It has inched up 0.66% over last one week and rose by 11.20% in last one month while the market capitalization of Rubicon Research Ltd has marginally improved by 4.29% and 69.31% in the same period respectively. Profit before tax (PBT) of Rubicon Research Ltd stood at Rs 110.37 crore in Q2 FY26, jumping 85.31% year-on-year, and heading higher 11.84% quarter-on-quarter. EBITDA came in at Rs 123 crore, surging by 57.29% YoY and easing 6.32% sequentially. Total expenses posted a minor rise of 3.16% to Rs 420.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 153.93 crore, marginally falling by 0.81% YoY, while employee benefits expense was at Rs 85.67 crore, soaring 25.34% YoY. For the TTM ended FY26, revenue from operations jumped by 36.57% to Rs 1753.96 crore, while net profit surged by 83.64% to Rs 246.74 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 26830% to Rs 392.51 crore, and PBT jumped 64.78% to Rs 320.53 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 205.05 crore in FY26, as against Rs 159.18 crore in FY25. Rubicon Research Ltd rallied 158.51% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.05% during the same period.
Rubicon Research Ltd share price slipped 2.03% to Rs 1622.0. The Company's net profit expanded by 10.41% to Rs 84.78 crore, while revenue from operations slightly gained 3.97% to Rs 534.34 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.63%. It has inched up 0.66% over last one week and rose by 11.20% in last one month while the market capitalization of Rubicon Research Ltd has marginally improved by 4.29% and 69.31% in the same period respectively. Profit before tax (PBT) of Rubicon Research Ltd stood at Rs 110.37 crore in Q2 FY26, jumping 85.31% year-on-year, and heading higher 11.84% quarter-on-quarter. EBITDA came in at Rs 123 crore, surging by 57.29% YoY and easing 6.32% sequentially. Total expenses posted a minor rise of 3.16% to Rs 420.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 153.93 crore, marginally falling by 0.81% YoY, while employee benefits expense was at Rs 85.67 crore, soaring 25.34% YoY. For the TTM ended FY26, revenue from operations jumped by 36.57% to Rs 1753.96 crore, while net profit surged by 83.64% to Rs 246.74 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 26830% to Rs 392.51 crore, and PBT jumped 64.78% to Rs 320.53 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 205.05 crore in FY26, as against Rs 159.18 crore in FY25. Rubicon Research Ltd rallied 158.51% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.05% during the same period.